Urol. praxi. 2024;25(3):130-135 | DOI: 10.36290/uro.2024.056

Hybrid imaging methods in diagnostics of prostatic carcinoma

prof. MUDr. Jiří Ferda, Ph.D., MUDr. Eva Ferdová
Klinika zobrazovacích metod LF UK a FN v Plzni

Imaging of the prostate tumour´s own tissue is using standard tumour imaging approaches remains difficult, the imaging using contrast enhanced computed tomography and also the hybrid imaging using PET/CT with the application of the 18F-fluorodeoxyglucose is insufficient. Magnetic resonance imaging is useful in detection of prostate cancer in patients with elevated prostatic specific antigen (PSA) and/or with increased prostate health index (PHI). Currently, it is possible to use combination of radiological and nuclear medicine methods - hybrid positron emission tomography combined with computed tomography (PET/CT) or with magnetic resonance imaging (PET/MRI) with the application of 18F-fluorocholine (FCH), 18F-fluciclovine, 18F-natriumfluoride (18F-NaF) or 68Ga-PSMA-11 (ligand of prostatic specific membrane antigen) in detection, staging or restaging of prostate carcinoma. PET/CT or PET/MRI with the application of 68Ga-PSMA-11 represents current optimal method for staging, restaging and evaluation of prostate cancer therapy response.

Keywords: prostate cancer, PET/MRI, PET/CT, 18F-fluorocholine, 18F-fluciclovine, 18F-natri­umfluoride, 68Ga-PSMA-11.

Accepted: October 1, 2024; Published: November 14, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ferda J, Ferdová E. Hybrid imaging methods in diagnostics of prostatic carcinoma. Urol. praxi. 2024;25(3):130-135. doi: 10.36290/uro.2024.056.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF

    References

    1. Eineluoto JT, Järvinen P, Kenttämies A, et al. Repeat multiparametric MRI in prostate cancer patients on active surveillance. PLoS One. 2017;12(12):e0189272. doi: 10.1371/journal.pone.0189272. eCollection 2017. PubMed PMID: 29281647. Go to original source...
    2. Brembilla G, Dell'Oglio P, Stabile A, et al. Preoperative multiparametric MRI of the prostate for the prediction of lymph node metastases in prostate cancer patients treated with extended pelvic lymph node dissection. Eur Radiol. 2017. doi: 10.1007/s00330-017-5229-6. [Epub ahead of print] PubMed PMID: 29270644. Go to original source... Go to PubMed...
    3. Kozlowski P, Chang SD, Jones EC, et al. Assessment of the need for DCE MRI in the detection of dominant lesions in the whole gland: Correlation between histology and MRI of prostate cancer. NMR Biomed. 2017. doi: 10.1002/nbm.3882. [Epub ahead of print] PubMed PMID: 29266527. Go to original source... Go to PubMed...
    4. Gaunay G, Patel V, Shah P, et al. Role of multi-parametric MRI, of the prostate for screening and staging: Experience with over 1500 cases. Asian J Urol. 2017;4(1):68-74. Go to original source... Go to PubMed...
    5. Druskin SC, Tosoian JJ, Young A, et al. Incorporating Prostate Health Index Density, MRI, and Prior Negative Biopsy Status to Improve the Detection of Clinically Significant Prostate Cancer. BJU Int. 2017. doi: 10.1111/bju.14098. [Epub ahead of print] PubMed PMID: 29232037. Go to original source... Go to PubMed...
    6. Mischinger J, Kaufmann S, Russo GI, et al. Targeted versus systematic robot-assisted transperineal MRI-TRUS fusion prostate biopsy. BJU Int. 2017. doi: 10.1111/bju.14089. [Epub ahead of print] PubMed PMID: 29211932. Go to original source... Go to PubMed...
    7. Schmid DT, John H, Zweifel R, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology. 2005;235(2):623-628. Go to original source... Go to PubMed...
    8. Cimitan M, Bortolus R, Morassut S, et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging. 2006;33(12):1387-1398. Go to original source... Go to PubMed...
    9. Kwee SA, Coel MN, Lim J. Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging. Ann Nucl Med. 2012;26(6):501-507. Go to original source... Go to PubMed...
    10. Graute V, Jansen N, Ubleis C, et al. Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. Eur J Nucl Med Mol Imaging. 2012;39(2):271-282. Go to original source... Go to PubMed...
    11. Kjölhede H, Ahlgren G, Almquist H, et al. Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer. BJU Int. 2012;110(10):1501-1506. Go to original source... Go to PubMed...
    12. Umbehr MH, Müntener M, Hany T, et al. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol. 2013;64(1):106-117. Go to original source... Go to PubMed...
    13. Dundee PE, Hutton AC, Eden CG. [<sup>1</sup>⁸F]-fluorocholine positron-emission/computed tomography for lymph node staging of patients with prostate cancer: preliminary results of a prospective study. BJU Int. 2011;107(1):158-159. Go to original source... Go to PubMed...
    14. Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a (68)Ga-labeled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11-20. Go to original source... Go to PubMed...
    15. Beer AJ, Eiber M, Souvatzoglou M, et al. Radionuclide and hybrid imaging of recurrent prostate cancer. Lancet Oncol. 2011;12(2):181-191. Go to original source... Go to PubMed...
    16. Castellucci P, Picchio M. 11C-choline PET/CT and PSA kinetics. Eur J Nucl Med Mol Imaging 2013;40(Suppl. 1):S36-S40. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.